U.S. Markets open in 9 hrs 5 mins
  • S&P Futures

    3,900.25
    -3.50 (-0.09%)
     
  • Dow Futures

    31,415.00
    -6.00 (-0.02%)
     
  • Nasdaq Futures

    12,023.00
    -17.50 (-0.15%)
     
  • Russell 2000 Futures

    1,770.40
    +0.60 (+0.03%)
     
  • Crude Oil

    110.96
    +1.39 (+1.27%)
     
  • Gold

    1,827.90
    +3.10 (+0.17%)
     
  • Silver

    21.19
    +0.02 (+0.10%)
     
  • EUR/USD

    1.0583
    -0.0003 (-0.0317%)
     
  • 10-Yr Bond

    3.1940
    +0.0690 (+2.21%)
     
  • Vix

    26.95
    -0.28 (-1.03%)
     
  • GBP/USD

    1.2275
    +0.0005 (+0.0393%)
     
  • USD/JPY

    135.2800
    -0.1660 (-0.1226%)
     
  • BTC-USD

    20,728.23
    -479.27 (-2.26%)
     
  • CMC Crypto 200

    450.30
    -11.50 (-2.49%)
     
  • FTSE 100

    7,258.32
    +49.51 (+0.69%)
     
  • Nikkei 225

    26,946.44
    +75.14 (+0.28%)
     

UNITY Biotechnology to Participate in the Cowen 42nd Annual Health Care Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
Unity Biotechnology, Inc.
Unity Biotechnology, Inc.

SOUTH SAN FRANCISCO, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that members of its senior management team will provide a corporate update and participate in one-on-one investor meetings at the Cowen 42nd Annual Health Care Conference taking place virtually on Monday, March 7, 2022, at 11:10 a.m. ET.

The presentation will be available through the Cowen conference portal and will also be available through the Investors & Media section of UNITY’s website. An archived replay will be available for 90 days following the event.

About UNITY

UNITY is developing a new class of therapeutics to slow, halt, or reverse diseases of aging. UNITY’s current focus is on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefit in age-related ophthalmologic and neurologic diseases. More information is available at www.unitybiotechnology.com or follow us on Twitter and LinkedIn.

Media Contact
Canale Communications
Jason Spark
Jason.spark@canalecomm.com

Investor Contact
LifeSci Advisors, LLC
Joyce Allaire
jallaire@lifesciadvisors.com